Ancient viral remnants in our genome may help predict response to chemotherapy
· Medical Xpressedited by Lisa Lock, reviewed by Andrew Zinin
Lisa Lock
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
In a new study, researchers from King's College London trained AI models on multiple types of clinical and biological data to determine whether they could predict which patients with acute myeloid leukemia (AML) would respond to chemotherapy. They found that behavior related to ancient viral sequences in the genome was associated with a poor response to treatment and that including this information made the models more accurate.
AML is a blood cancer that originates in the bone marrow. Despite using multiple tests, doctors cannot reliably predict whether patients will respond to chemotherapy. Many patients develop refractory AML, meaning they do not achieve full remission even though they receive treatment.
The study, published in Blood Neoplasia, looked at data from 271 AML patients who received standard chemotherapy. The researchers created three multilayer machine-learning models, progressively adding different types of clinical and biological data. The final model also included information relating to the activity of remnants of ancient viruses, also known as endogenous retroviruses (ERVs).
ERVs comprise remnants of ancient viruses that infected our evolutionary ancestors millions of years ago and became incorporated into the genome. They are found within the noncoding parts of our genome, some of which remain poorly understood and are sometimes referred to as the "dark genome." ERVs can influence a variety of biological mechanisms, including which genes are switched on, immune signaling and more.
When ERV behavior data were combined with the other data, the model's ability to predict who would respond to chemotherapy improved. This model also had fewer false positives compared with other versions—that is, predicting a patient would have refractory AML when they may have responded to treatment.
The researchers believe ERV activity could be linked to "viral mimicry," where the cell responds as though viral activity is taking place. This can trigger immune and inflammatory signaling, which may help sustain the treatment-resistant state of some AML cells. However, further research is needed to determine whether this process directly causes chemotherapy resistance.
"Most cancer studies focus on conventional genes. However, the so-called dark genome—which makes up large parts of our DNA—remains overlooked. We identified a signature from ancient viral sequences within the dark genome that added valuable information to conventional gene-expression approaches for predicting chemotherapy response in acute myeloid leukemia.
"Although further clinical validation is required, our findings demonstrate the potential of the dark genome to help identify high-risk patients earlier and guide more personalized treatment strategies," said lead author Dr. Mohammad Mahdi Karimi, senior lecturer in bioinformatics at King's College London.
Patient data was provided by the Beat AML clinical trial—a landmark precision medicine clinical trial launched in 2016 by Blood Cancer United.
More information
Nogayhan Seymen et al, Multilayer modeling reveals an endogenous retrovirus signature predictive of induction chemotherapy failure in AML, Blood Neoplasia (2026). DOI: 10.1016/j.bneo.2026.100263
Key medical concepts
Clinical categories
Oncology Provided by King's College London Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Ancient viral remnants in our genome may help predict response to chemotherapy (2026, September 10) retrieved 10 September 2026 from https://medicalxpress.com/news/2026-09-ancient-viral-remnants-genome-response.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.